IFPMA, BIO and WADA advance anti-doping collaboration

IFPMA, BIO and WADA advance anti-doping collaboration with the launch of 2 Fields 1 Goal Campaign 

Groups Issue Booklet to Help Biotechnology and Pharmaceutical Companies Identify Pipeline Medicines with Doping Potential 

GENEVA, WASHINGTON, D.C. and MONTREAL, JULY 23, 2012 – The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the global Biotechnology Industry Organization (BIO) and the World Anti-Doping Agency (WADA) today announced the launch of the 2 FIELDS 1 GOALProtecting the Integrity of Science and Sport campaign, that aims to achieve the goals of the Joint Declaration on Cooperation in the Fight against Doping in Sport (Joint Declaration).


The campaign creates a strong framework of collaboration and encourages the voluntary cooperation of IFPMA and BIO member companies with WADA to readily identify compounds with the potential for misuse by athletes and to stop doping in sport.

The launch of the 2 FIELDS 1 GOAL campaign coincides with the release of the Points to Consider: Identification of Compounds with Potential for Doping Abuse and Sharing of Information with WADA (Points to Consider) booklet. This resource provides biotechnology and pharmaceutical companies with practical guidelines to identify compounds with sports-related doping potential before they come to market. The Points to Consider booklet also helps minimize misuse of compounds during clinical trials, facilitates sharing of information and collaboration on communications about medicines with known doping potential. In addition to the booklet, campaign materials include a brochure and frequently asked questions, which provide more insight into industry collaboration against doping in sport.

“The 2 FIELDS 1 GOAL campaign aims to accomplish the goals that were laid out in the Joint Declaration that IFPMA and BIO signed with WADA,” said Eduardo Pisani, IFPMA Director General. “Doping is a public health issue and undermines the integrity of scientific innovation and competitive sports. We are pleased to provide support that will help companies determine if they have products in their pipelines that could be abused by athletes, even before they come to market.”

“Working closely with biotechnology and pharmaceutical companies to identify new potential doping compounds before they are commercially available will facilitate much faster development of detection methods,” said David Howman, Director General of WADA. “In addition, the booklet will allow the pharmaceutical industry to ensure their work is directed at developing and delivering treatments and medicines for therapeutic purposes.”
For a copy of the Points to Consider booklet and campaign materials, please visit www.ifpma.org/ethics/doping-in-sport.html.

———–
Terence O’Rorke
WADA
Senior Manager, Media Relations and Communications